



ASX / MEDIA RELEASE

3rd February 2017

Interim CEO Remuneration

Sydney, Australia; 3rd February 2017 – Sirtex Medical Limited (ASX:SRX) today provides the material terms of the Employment Agreement concluded between Sirtex Medical Limited (the Company) and Mr Nigel Lange for the role of Interim Chief Executive Officer (CEO).

Commencement Date as Interim CEO	13 th January 2017
Term	No fixed term. The agreement is ongoing until the Board appoints a permanent CEO.
Total Fixed Remuneration (TFR)	\$740,000 per annum including superannuation pro-rated for the period as Interim CEO.
Short Term Incentive (STI) for 2017	<p>Maximum 'at risk' component of remuneration is 40% of TFR. This component is subject to company and individual performance and is provided in cash.</p> <p>In light of Mr Lange's appointment as acting CEO, the Board will review his KPI's for FY17. Further information will be provided in the Company's Remuneration Report for the year ended 30th June, 2017.</p> <p>STI participation and terms in future years are at the absolute discretion of the Board.</p>
Long Term Incentive (LTI) for 2017	<p>75% of TFR.</p> <p>The Sirtex Executive Rights Plan (LTI) provides Executive employees with an 'at risk' component of remuneration based on company performance over a 3-year period and is delivered as equity if specified hurdles are met.</p> <p>Mr Lange has already received an Executive Rights Allocation in respect to FY17, which will remain, in accordance with their original terms.</p> <p>Participation in the LTI Plan is subject to the rules of the Plan and are at the absolute discretion of the Board.</p>

Termination Of Employment
from Sirtex

Six months' notice in writing by either party.

Sirtex may terminate Mr Lange employment with immediate effect for cause (for example, serious misconduct or serious negligence).

Termination entitlements

Six months when employment is terminated from Sirtex.

Post-Employment Restraint

Maximum restraint period of 12 months.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Darren Smith
CFO and Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd